MSD
High-Risk Patients
References
  1. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488–1497.
     
  2. Januzzi JL, Snapinn SM, DiBattiste PM et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency. Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial. Circulation 2002;105:2361–2366.
     
  3. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non–ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767–2771.
     
  4. Heeschen C, Hamm CW, Goldmann B et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757–1762.
     
  5. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–1505.
AGGRASTAT is a registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA